Difference between revisions of "T-cell prolymphocytic leukemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(added some regimens, reference. please confirm that early clinical reports/abstracts are ok (ven/ibrutinib regimen))
Tag: visualeditor
Line 1: Line 1:
 
{| class="wikitable" style="text-align:center; width:50%;"
 
{| class="wikitable" style="text-align:center; width:50%;"
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
+
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26" |'''Section editor'''
 
|-
 
|-
−
|style="background-color:#F0F0F0"|[[File:Bdholaria.jpg|frameless|upright=0.3|center]]
+
| style="background-color:#F0F0F0" |[[File:Bdholaria.jpg|frameless|upright=0.3|center]]
 
|<big>[[User:Bdholaria|Bhagirathbhai Dholaria, MBBS]]<br>Vanderbilt University<br>Nashville, TN</big>
 
|<big>[[User:Bdholaria|Bhagirathbhai Dholaria, MBBS]]<br>Vanderbilt University<br>Nashville, TN</big>
 
|-
 
|-
Line 15: Line 15:
 
=Guidelines=
 
=Guidelines=
 
==[https://www.nccn.org/ NCCN]==
 
==[https://www.nccn.org/ NCCN]==
 +
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
−
==TPLL-ISG==
+
 
 +
==Diagnosis, staging and treatment response criteria (TPLL-ISG)==
 +
 
 
*'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia]
 
*'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia]
  
−
=All lines of therapy=
+
=Upfront induction therapy=
 
==Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}==
 
==Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
Line 27: Line 30:
 
===Regimen {{#subobject:893a|Variant=1}}===
 
===Regimen {{#subobject:893a|Variant=1}}===
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!style="width: 25%"|Study
+
! style="width: 25%" |Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
!Efficacy
 
|-
 
|-
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 Dearden et al. 2001]
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 Dearden et al. 2001]
−
|style="background-color:#91cf61"|Non-randomized
+
| style="background-color:#91cf61" |Non-randomized
 +
|ORR: 76%, CR: 60%
 
|-
 
|-
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 Dearden et al. 2011]
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 Dearden et al. 2011]
−
|style="background-color:#91cf61"|Non-randomized
+
| style="background-color:#91cf61" |Non-randomized
 +
|ORR: 91%, CR: 81%
 
|-
 
|-
 
|}
 
|}
 
====Chemotherapy====
 
====Chemotherapy====
−
*[[Alemtuzumab (Campath)]]
+
 
 +
* [[Alemtuzumab (Campath)]]
 +
 
 +
First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
 +
 
 +
<big>'''<u>Alemtuzumab, Pentostatin</u>'''</big>
 +
 
 +
'''Regimen'''
 +
{| class="wikitable" style="width: 50%; text-align:center;"
 +
! style="width: 25%" |Study
 +
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
!Efficacy
 +
|-
 +
![https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 '''Ravandi et al. 2009''']
 +
!'''Non-randomized'''
 +
!ORR: 69%, CR: 62%
 +
|}<br />
 +
====Chemotherapy====
 +
 
 +
*[[Alemtuzumab (Campath)]] First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
 +
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)
  
 
===References===
 
===References===
−
# Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11535503 PubMed]
+
 
−
# Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21948296 PubMed]
+
#Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11535503 PubMed]
 +
#Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21948296 PubMed]
 +
#Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 PubMed]
 +
 
 +
'''<u><big>Relapsed or refractory, salvage therapy</big></u>'''
 +
 
 +
<big>'''<u>Alemtuzumab, Pentostatin</u>'''</big>
 +
 
 +
'''Regimen'''
 +
{| class="wikitable" style="width: 50%; text-align:center;"
 +
! style="width: 25%" |Study
 +
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
!Efficacy
 +
|-
 +
![https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 '''Ravandi et al. 2009''']
 +
!'''Non-randomized'''
 +
!ORR: 69%, CR: 62%
 +
|}<br />
 +
====Chemotherapy====
 +
 
 +
*[[Alemtuzumab (Campath)]] First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
 +
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)
 +
 
 +
'''References'''
 +
 
 +
# Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 PubMed]
 +
 
 +
'''<big><u>Bendamustine</u></big>'''
 +
 
 +
Regimen
 +
{| class="wikitable" style="width: 50%; text-align:center;"
 +
! style="width: 25%" |Study
 +
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
!Herbaux et al. 2014
 +
!Retrospective
 +
|}
 +
 
 +
* [[Bendamustine (Treanda)|Bendamustine]] 70 to 120 mg/m<sup>2</sup> IV, days 1 and 2 every 3 weeks for total 6 cycles
 +
 
 +
'''References'''
 +
 
 +
# Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S,  Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9.[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13175 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=25316212 PubMed] <br />
 +
 
 +
'''<big><u>Venetoclax, Ibrutinib</u></big>''' (ongoing clinical trial, [https://clinicaltrials.gov/ct2/show/NCT03873493 NCT03873493])
 +
 
 +
Regimen
 +
 
 +
* [[Venetoclax (Venclexta)|Venetoclax]] 400 mg, potentially up to 600 mg, orally once daily
 +
* [[Ibrutinib (Imbruvica)|Ibrutinib]] 420 mg dosed orally once daily
 +
 
 +
'''References'''
 +
 
 +
# Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965.[https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases?searchresult=1 link to original article]
 +
 
 +
'''<big><u>Consolidation therapy after upfront or salvage therapy</u></big>'''
 +
 
 +
'''[[Allogeneic HSCT]]''' evaluation suggested in eligible patients.
 +
 
 +
'''<big>References</big>'''
 +
 
 +
# Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2010.08134.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=20201944 PubMed]
 +
# Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz  MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. [https://www.sciencedirect.com/science/article/pii/S1083879109005813?via%3Dihub link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19961946 PubMed]
 +
# Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond  V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6.[https://www.nature.com/articles/leu2011304 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=22116553 PubMed]
  
 
[[Category:T-cell prolymphocytic leukemia regimens]]
 
[[Category:T-cell prolymphocytic leukemia regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:T-cell leukemias]]
 
[[Category:T-cell leukemias]]

Revision as of 20:53, 7 January 2020

Section editor
Bdholaria.jpg
 Bhagirathbhai Dholaria, MBBS
Vanderbilt University
Nashville, TN
5 regimens on this page
5 variants on this page


Guidelines

NCCN

Diagnosis, staging and treatment response criteria (TPLL-ISG)

Upfront induction therapy

Alemtuzumab monotherapy

back to top

Regimen

Study Evidence Efficacy
Dearden et al. 2001 Non-randomized ORR: 76%, CR: 60%
Dearden et al. 2011 Non-randomized ORR: 91%, CR: 81%

Chemotherapy

First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months

Alemtuzumab, Pentostatin

Regimen

Study Evidence Efficacy
Ravandi et al. 2009 Non-randomized ORR: 69%, CR: 62%


Chemotherapy

  • Alemtuzumab (Campath) First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
  • Pentostatin (Nipent) 4 mg/m2 IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)

References

  1. Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. link to original article PubMed
  2. Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. link to original article PubMed
  3. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. link to original article PubMed

Relapsed or refractory, salvage therapy

Alemtuzumab, Pentostatin

Regimen

Study Evidence Efficacy
Ravandi et al. 2009 Non-randomized ORR: 69%, CR: 62%


Chemotherapy

  • Alemtuzumab (Campath) First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
  • Pentostatin (Nipent) 4 mg/m2 IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)

References

  1. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. link to original article PubMed

Bendamustine

Regimen

Study Evidence
Herbaux et al. 2014 Retrospective
  • Bendamustine 70 to 120 mg/m2 IV, days 1 and 2 every 3 weeks for total 6 cycles

References

  1. Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9.link to original article PubMed

Venetoclax, Ibrutinib (ongoing clinical trial, NCT03873493)

Regimen

  • Venetoclax 400 mg, potentially up to 600 mg, orally once daily
  • Ibrutinib 420 mg dosed orally once daily

References

  1. Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965.link to original article

Consolidation therapy after upfront or salvage therapy

Allogeneic HSCT evaluation suggested in eligible patients.

References

  1. Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. link to original article PubMed
  2. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. link to original article PubMed
  3. Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6.link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=T-cell_prolymphocytic_leukemia&oldid=41745"